表紙
市場調査レポート

遺伝子サイレンシング(2010年):シリーズ 3

2010 Gene Silencing Dashboard Series 3

発行 Percepta Associates Inc. 商品コード 136244
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
遺伝子サイレンシング(2010年):シリーズ 3 2010 Gene Silencing Dashboard Series 3
出版日: 2010年10月29日 ページ情報: 英文

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当報告書では、北米および欧州の281名の科学者らにインタビューを行ない、遺伝子サイレンシング(遺伝子抑制)製品市場の特性と動向、新製品開発、競合、売上、マーケティング戦略などについてまとめ、概略下記の構成で取り上げております。

  • エグゼクティブサマリー
  • 主な調査結果と影響
  • 遺伝子サイレンシング
  • 遺伝子サイレンシング市場機会マトリクス
  • 調査方法
  • 調査に関する案内文
  • 回答者人口統計
  • ライフサイエンス技術実績頻度
  • 遺伝子サイレンシング技法の実施頻度
  • 反応処理量と市場成長率
  • 回答者の反応あたりの価格
  • 市場全体の規模、セグメント別の規模、市場全体の成長率
  • セグメント別市場シェア
  • 顧客満足度とサプライヤー変更への関心
  • 購買決定に影響を及ぼす製品特性
  • 主な用途
  • 遺伝子サイレンシング製品に望まれる変化
  • 調査質問事項
  • 図表
目次
Product Code: 1010GSL

RNA interference continues to emerge as a integral tool used to study the physiological role of gene products in vivo. RNAi-based methods allow researchers to modulate and in many cases virtually eliminate expression of a gene of interest. Systems for delivering RNAs into cells for the purpose of gene silencing include standard transfection technologies, both instrument-mediated and lipid-based, as well as plasmid and viral systems for the inducible expression of siRNAs in vivo.

Percepta' s 2010 Gene Silencing Dashboard™ dives deeply into the characteristics and dynamics of the market for gene silencing products. This 2010 Dashboard provides a snapshot of the current market landscape that can be compared with data from the 2008 and 2007 Gene Silencing Dashboard, providing an ongoing story of how the market is adapting to new products, new competitors and new sales and marketing strategies.

The Gene Silencing Dashboard™ was developed from responses to a 21-question survey completed by 281 scientists predominantly located in North America and Europe. This Dashboard reveals key market indicators for the gene silencing market as a whole as well as for the following methods representing market sub-segments:

  • RNAi screens using siRNA libraries (sets of 50 or more siRNAs)
  • Inducing siRNAs in vivo from a plasmid or other vector in cells
  • Digesting long dsRNA in vivo using dicer or other enzymes
  • Expressing siRNA in vitro for delivery into cells
  • Using PCS mediated siRNA expression cassettes to generate siRNAs
  • Instrument mediated delivery of synthetic siRNAs into cells
  • Lipid mediated delivery of synthetic siRNAs into cells
  • Instrument mediated delivery of plasmids into cells for plasmid-based gene knockdown
  • Lipid mediated delivery of plasmids into cells for plasmid-based gene knockdown
  • Viral delivery of vectors into cells for vector-based gene knockdown
  • Using reporter systems to track gene knockdown

Respondent Demographics

Respondents from the academic, government and commercial market segments are well represented, with 20.8% of respondents employed in an industry setting. 73.0% of respondents are from North America, while 25.1% reside in Europe.

Junior (Lab Tech, Grad Students), mid level (Post-Doc, Lab Manager) and senior (Professor/PI, Group Leader) scientists are well represented in the data set, with the most cited job titles being Scientist/Senior Scientist (24.7% of respondents) and Professor / Principle Investigator (20.8%).

A wide variety of scientific areas of specialization is also evident, led by molecular biology (named by 28.9% of respondents as their primary area of expertise) and cell biology (named by 17.0% of respondents). Oncology research (9.1%) and biochemistry (7.1%) are the only other applications named by more than 7% of respondents.

Small (1-5 scientists), medium (6-20 scientists) and large (>20 scientists) laboratories are well represented: 36.1% of respondents work in labs where 1 to 5 people perform experiments; 51.2% in labs with 6 to 20 experimenters, and the remaining 12.7% in labs with greater than 20 bench scientists.

60.1% of respondents indicated that 1 to 3 people in their laboratories perform gene silencing experiments. An additional 18.5% of survey participants revealed that 4 or 5 individuals perform gene silencing experiments in their labs. Only 7.3% of respondents work in labs where greater than 10 people perform gene silencing experiments.

Table of Contents

  • 6. Figures and Tables
  • 10. Executive Summary
  • 13. Key Findings and Implications
  • 18. Gene Silencing Dashboard
  • 23. Gene Silencing Market Opportunity Matrix
  • 25. Survey Methodology
  • 27. Survey Invitation Text
  • 28. Respondent Demographics
  • 41. Frequency of Performance of Life Science Techniques
  • 46. Frequency of Performance of Various Gene Silencing Methods
  • 73. Reaction Throughput and Market Segment Growth Rates
  • 80. Respondent' s Stated Price Per Reaction
  • 83. Total Market Size, Market Segment Sizes and Total Market Growth Rate
  • 85. Market Shares by Segment (Share of Mention)
  • 119. Customer Satisfaction And Interest In Switching Suppliers
  • 125. Product Features That Influence Purchasing Decisions
  • 129. Primary Downstream Applications
  • 146. Desired Changes to Gene Silencing Products
  • 152. Survey Questionnaire

Figures and Tables

  • 30. Figure 1: Respondent' s Place of Employment
  • 32. Figure 2: Respondent' s Country/Region
  • 34. Figure 3: Respondent' s Job Title
  • 36. Figure 4A: Respondent' s Areas of Expertise/Specialization
  • 37. Figure 4B: Respondent' s Areas of Expertise/Specialization (Molecular Biology Excluded)
  • 40. Figure 5: Number of Employees in Respondent' s Laboratories
  • 43. Figure 6: Percentage of Respondents Performing Various Life Science Techniques at Least a Few Times per Year
  • 49. Figure 7: Percentage of Respondents Performing RNAi/siRNA Experiments
  • 50. Figure 7A: Change in Percentage of Respondents Performing RNAi/siRNA Experiments
  • 51. Figure 8: Percentage of Respondents Performing Various Gene Silencing Techniques at Least a Few Times per Year
  • 53. Figure 9: Percentage of Respondents That Perform RNAi Screens Using siRNA Libraries
  • 54. Figure 9A: Change in Percentage of Respondents that Perform RNAi Screens Using siRNA Libraries
  • 55. Figure 10: Percentage of Respondents That Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 56. Figure 10A: Change in Percentage of Respondents that Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 57. Figure 11: Percentage of Respondents That Digest Long dsRNA in vivo using Dicer or other Enzymes
  • 58. Figure 11A: Change in Percentage of Respondents that Digest Long ds RNA in vivo using Dicer or other Enzymes
  • 59. Figure 12: Percentage of Respondents that Express siRNA in vitro for Delivery into Cells
  • 60. Figure 12A: Change in Percentage of Respondents that Express siRNA in vitro for Delivery into Cells
  • 61. Figure 13: Percentage of Respondents that Use PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 62. Figure 13A: Change in Percentage of Respondents that Use PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 63. Figure 14: Percentage of Respondents that Deliver Synthetic siRNAs into Cells (Instrument Mediated)
  • 64. Figure 15: Percentage of Respondents that Deliver Synthetic siRNAs into Cells (Lipid Mediated)
  • 65. Figure 16: Percentage of Respondents that Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Instrument Mediated)
  • 66. Figure 17: Percentage of Respondents that Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Lipid Mediated)
  • 67. Figure 18: Percentage of Respondents that Deliver Viral Vectors into Cells for Vector Based Gene Knockdown
  • 68. Figure 19: Percentage of Respondents that Use a Reporter Systems to Track Gene Knockdown
  • 69. Figure 19A: Change in Percentage of Respondents that Use a Reporter Systems to Track Gene Knockdown
  • 90. Figure 20: Respondent' s Primary Supplier of Products for Performing RNAi Screens Using siRNA Libraries
  • 91. Figure 20A: Changes in Respondent' s Primary Supplier of Products for Performing RNAi Screens Using siRNA Libraries
  • 93. Figure 21: Respondent' s Primary Supplier of Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 94. Figure 21A: Changes in Respondent' s Primary Supplier of Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 96. Figure 22: Respondent' s Primary Supplier of Products to Digest Long ds RNA in vivo using Dicer or Other Enzymes
  • 97. Figure 22A: Changes in Respondent' s Primary Supplier of Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
  • 99. Figure 23: Respondent' s Primary Supplier of Products to Express siRNA in vitro for Delivery into Cells
  • 100. Figure 23A: Changes in Respondent' s Primary Supplier of Products to Express siRNA in vitro for Delivery into Cells
  • 102. Figure 24: Respondent' s Primary Supplier of PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 103. Figure 24A: Changes in Respondent' s Primary Supplier of PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 105. Figure 25: Respondent' s Primary Supplier of Products to Deliver Synthetic siRNAs into Cells (Instrument Mediated)
  • 107. Figure 26: Respondent' s Primary Supplier of Products to Deliver Synthetic siRNAs into Cells (Lipid Mediated)
  • 109. Figure 27: Respondent' s Primary Supplier of Products to Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Instrument Mediated)
  • 111. Figure 28: Respondent' s Primary Supplier of Products to Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Lipid Mediated)
  • 113. Figure 29: Respondent' s Primary Supplier of Products for Viral Delivery of Vectors into Cells for Vector Based Gene Knockdown
  • 115. Figure 30: Respondent' s Primary Supplier of Reporter Systems to Track Gene Knockdown
  • 116. Figure 30A: Changes in Respondent' s Primary Supplier of Reporter Systems to Track Gene Knockdown
  • 124. Figure 31: Percentage of Respondents That Have Switched Suppliers in the Last Six Months
  • 127. Figure 32: Most Important Features of Products for Gene Silencing Experiments
  • 132. Figure 33: Respondent' s Primary Downstream Application for RNAi Screens Using siRNA Libraries
  • 133. Figure 34: Respondent' s Primary Downstream Application for Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 134. Figure 35: Respondent' s Primary Downstream Application for Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
  • 135. Figure 36: Respondent' s Primary Downstream Application for Products to Express siRNA in vitro for Delivery into Cells
  • 136. Figure 37: Respondent' s Primary Downstream Application for PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 137. Figure 38: Respondent' s Primary Downstream Application for Products to Deliver Synthetic siRNAs into Cells (Instrument Mediated)
  • 138. Figure 39: Respondent' s Primary Downstream Application for Products to Deliver Synthetic siRNAs into Cells (Lipid Mediated)
  • 139. Figure 40: Respondent' s Primary Downstream Application for Products to Deliver Plasmids into Cells for Gene Knockdown (Instrument Mediated)
  • 140. Figure 41: Respondent' s Primary Downstream Application for Products to Deliver Plasmids into Cells for Gene Knockdown (Lipid Mediated)
  • 141. Figure 42: Respondent' s Primary Downstream Application for Products to Deliver Viral Vectors into Cells for Vector Based Gene Knockdown
  • 142. Figure 43: Respondent' s Primary Downstream Application for Reporter Systems to Track Gene Knockdown
  • 38. Table 1: Respondent' s Areas of Expertise/Specialization Values for Figures 4A and 4B
  • 44. Table 2: Frequency of Performance of Various Life Science Techniques
  • 45. Table 3: Frequency of Co-Performance of Various Life Science Techniques
  • 52. Table 4: Frequency of Performance of Gene Silencing Methods
  • 71. Table 5: Frequency of Co-Performance of Life Science Techniques with Gene Silencing Methods
  • 72. Table 6: Frequency of Co-Performance of Gene Silencing Methods with Life Science Techniques
  • 75. Table 7: Median and Average Monthly Throughput for Gene Silencing Products
  • 76. Table 8: Percentage of Respondents Performing Various Numbers of Gene Silencing Reactions Per Month
  • 77. Table 9: Comparison to 2008 Dashboard of the Percentage of Respondents Performing Various Numbers of Gene Silencing Reactions Per Month
  • 79. Table 10: Projected Growth in the Performance of Various Gene Silencing Techniques
  • 82. Table 11: Median and Average Price Per Prep for Gene Silencing Products
  • 118. Table 12: Market Share Leaders for Gene Silencing Products
  • 121. Table 13: Percentage of Respondents Satisfied with Various Gene Silencing Products and Reasons for Dissatisfaction
  • 122. Table 14: Percentage of Respondents Satisfied with Various Gene Silencing Products: Comparison to 2008 Dashboard
  • 128. Table 15: Most Important Features of Products for Gene Silencing Experiments - Comparison to 2008 Gene Silencing Dashboard
  • 143. Table 16: Respondent' s Primary Application for Various Gene Silencing Methods
  • 145. Table 17: Respondent' s Primary Application for Various Gene Silencing Methods - Comparison to 2008 Gene Silencing Dashboard
Back to Top